Goldman Sachs lowered the firm’s price target on Biogen (BIIB) to $245 from $281 but keeps a Buy rating on the shares. The firm cites the ...

Biogen expects 2025 non-GAAP EPS of $15.25-$16.25 and a mid-single-digit decline in total revenue, primarily due to MS franchise pressures, including potential biosimilar and generic entries. Growth ...

Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is ...

Q4 2024 Earnings Conference Call February 12, 2025 8:30 AM ETCompany ParticipantsTim Power - Head of IRChris Viehbacher ...

based Biogen had net income of $266.8 million ... The company is now expecting 2025 EPS to range from $15.25 to $16.25, below the $16.33 FactSet consensus. Revenue is expected to decline by a ...

Sales of an Alzheimer’s disease treatment were better than expected, but that and a quarterly beat wasn’t enough to offset ...

Cambridge, USA-based biotech Sage Therapeutics yesterday announced that, while rejecting an unsolicited takeover offer, its board of directors has initiated a process to explore strategic alternatives ...

In the following chart, we are able to follow the development of volume and open interest of call and put options for Biogen's big money trades within a strike price range of $115.0 to $260.0 over ...

Two years ago, Biogen and partner Eisai secured accelerated ... Novartis has sales potential in the $3 billion to $8 billion range, along with Entresto and Cosentyx, plus more recent launches ...